Background/Aims: Gait apraxia characterized primarily by gait ignition failure has been linked to lesions involving the dorsomedial frontal lobes, but the precise locus within this general region has not been determined. It has previously been hypothesized by Thompson and Marsden that disease, disconnection, or dysfunction of supplementary motor area (SMA) may account for the similarities in the gait disorders observed in Binswanger’s disease, hydrocephalus, frontal lobe lesions, and Parkinson’s disease. We reevaluate this hypothesis. Methods: Clinical description and MRI of 2 subjects with gait apraxia characterized primarily by gait ignition failure. Results: Both subjects had incapacitating gait disorders characterized by particular difficulty with initiating gait and making turns. Both had MRI-demonstrated lesions of the SMA region, parasagittal convexity premotor cortex, or subjacent white matter bilaterally, one due to primary CNS lymphoma, one due to a lobar atrophy. Conclusions: In both these cases, the lesions were substantially more limited and focal than any reported heretofore in the literature on gait apraxia or freezing of gait. The clinicopathologic correlation in these cases provides partial support for the Thompson and Marsden hypothesis, but also may implicate parasagittal convexity premotor cortex in the genesis of gait apraxia.

Keywords:
Gait apraxia, Supplementary motor area, Gait ignition failure, Primary progressive freezing gait
1.
Della Sala S, Francescani A, Spinnler H: Gait apraxia after bilateral supplementary motor area lesion. J Neurol Neurosurg Psychiatry 2002;72:77–85.
2.
Meyer JS, Barron DW: Apraxia of gait: a clinico-physiological study. Brain 1960;83:261–284.
3.
Denny-Brown D: The nature of apraxia. J Nerv Ment Dis 1958;126:9–31.
4.
Rossor MN, Tyrrell PJ, Warrington EK, Thompson PD, Marsden CD, Lantos P: Progressive frontal gait disturbance with atypical Alzheimer’s disease and corticobasal degeneration. J Neurol Neurosurg Psychiatry 1999;67:345–352.
5.
Miyai I, Tanabe HC, Sase I, Eda H, Oda I, Konishi I, et al: Cortical mapping of gait in humans: a near-infrared spectroscopic topography study. Neuroimage 2001;14:1186–1192.
6.
Nadeau SE, McCoy KJM, Crucian GP, Greer RA, Rossi F, Bowers D, et al: Cerebral blood flow changes in depressed patients after treatment with repetitive transcranial magnetic stimulation: evidence of individual variability. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:159–175.
7.
Alexander MP, Stuss DT, Picton T, Shallice T, Gillingham S: Regional frontal injuries cause distinct impairments in cognitive control. Neurology, in press.
8.
Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, et al: Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56:399–406.
9.
Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG: The evolution and pathology of frontotemporal dementia. Brain 2005;128:1996–2005.
10.
Stark M, Coslett HB, Saffran EM: Impairment of an egocentric map of locations: implications for perception and action. Cogn Neuropsychol 1996;13:481–523.
11.
Factor SA, Higgins DS, Qian : Primary progressive freezing gait: a syndrome with many causes. Neurology 2006;66:411–414.
12.
Factor SA, Jennings DL, Molho ES, Marek KL: The natural history of the syndrome of primary progressive freezing gait. Arch Neurol 2002;59:1778–1783.
13.
Fabre N, Brefel C, Sabatini U, Celsis P, Montastruc JL, Chollet F, et al: Normal frontal perfusion in patients with frozen gait. Mov Disord 1998;13:677–683.
14.
Thompson PD, Marsden CD: Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger’s disease. Movement Disorders 1987;2:1–8.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.